Skip to main content
    C

    Co-Diagnostics, Inc. Common Stock (CODX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.72
    -0.05 (-6.46%)

    Market Cap: $6.49M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(14/31)
    Avg Surprise
    -129.85%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.25
    Range$-1.25 - $-1.25
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-2.85+56.1%
    60d ago$-3.30+62.1%
    30d ago$-3.30+62.1%
    7d ago$-3.30+62.1%
    Current$-1.25
    Revenue Consensus
    $169000
    Range$169000 - $169000
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$4.90
    Range$4.90 - $4.90
    1 analysts
    Revenue Consensus
    $188500
    Range$188500 - $188500
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$4.90---
    Sep 26EST
    		-$-1.25---
    Jun 26
    Reported Aug 13
    		$-1.46N/A+51.33%Beat+79.2%
    Mar 26
    Reported May 14
    		$-4.09$-3.75-9.07%Miss+47.0%
    Dec 25
    Reported Mar 31
    		$-4.44$-0.13-3314.46%Miss-1074.9%
    Sep 25
    Reported Nov 13
    		$-4.66$-5.70+18.25%Beat+52.5%
    Jun 25
    Reported Aug 14
    		$-7.01$-7.50+6.53%Beat+6.5%
    Mar 25
    Reported May 8
    		$-7.72$-9.90+22.02%Beat+21.3%
    Dec 24
    Reported Mar 27
    		$-0.38$-0.34-11.12%Miss+24.4%
    Sep 24
    Reported Nov 7
    		$-9.82$-9.90+0.81%Beat-50.2%
    Jun 24
    Reported Aug 8
    		$-7.50$-10.20+26.47%Beat+21.1%
    Mar 24
    Reported May 9
    		$-9.81$-6.30-55.71%Miss-42.0%
    Dec 23
    Reported Mar 14
    		$-0.50$-0.20-150.00%Miss+26.5%
    Sep 23
    Reported Nov 9
    		$-6.54$-8.70+24.83%Beat-174.8%
    Jun 23
    Reported Aug 10
    		$-9.50$-7.20-31.94%Miss-226.5%
    Mar 23
    Reported May 11
    		$-6.91$-7.20+4.03%Beat-190.4%
    Dec 22
    Reported Mar 16
    		$-0.68$-0.15-353.33%Miss-372.0%
    Sep 22
    Reported Nov 10
    		$-2.38$-1.00-138.00%Miss-120.9%
    Jun 22
    Reported Aug 11
    		$-2.91$2.10-238.57%Miss-129.4%
    Mar 22
    Reported May 12
    		$7.64$5.10+49.80%Beat-2.1%
    Dec 21
    Reported Mar 24
    		$0.25$0.12+108.33%Beat-44.4%
    Sep 21
    Reported Nov 11
    		$11.40$6.30+80.95%Beat-28.3%
    Jun 21
    Reported Aug 12
    		$9.90$6.60+50.00%Beat-23.3%
    Mar 21
    Reported May 13
    		$7.80$6.00+30.00%Beat+620.0%
    Dec 20
    Reported Mar 25
    		$0.45$0.48-6.25%Miss+600.0%
    Sep 20
    Reported Nov 16
    		$15.90$21.15-24.82%Miss+630.0%
    Jun 20
    Reported Aug 13
    		$12.90$19.50-33.85%Miss+637.5%
    Mar 20
    Reported May 14
    		$-1.50$-1.20-25.00%Miss+44.4%
    Dec 19
    Reported Mar 30
    		$-0.09$-0.09+0.00%Beat+40.0%
    Sep 19
    Reported Nov 13
    		$-3.00$-2.25-33.33%Miss-2207.7%
    Jun 19
    Reported Aug 14
    		$-2.40$-1.65-45.45%Miss-2081.8%
    Mar 19
    Reported Apr 2
    		$-2.70$-2.40-12.50%Miss-2354.5%
    Dec 18
    Reported Dec 31
    		$-0.15$-0.13-15.38%Miss-25.0%
    Sep 18
    Reported Nov 14
    		$-0.13N/AN/ABeat+60.6%
    Jun 18
    Reported Aug 10
    		$-0.11N/AN/ABeat-57.1%
    Mar 18
    Reported May 14
    		$-0.11N/AN/ABeat-
    Dec 17
    Reported Mar 28
    		$-0.12N/AN/ABeat-
    Sep 17
    Reported Nov 14
    		$-0.33N/AN/ABeat-
    Jun 17
    Reported Aug 25
    		$-0.07$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.05EV/EBITDAN/A
    Price/FCF-0.11xFCF Yield-891.30%
    Profitability
    Profit Margin0.00%Operating Margin-3732.00%
    ROE-174.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio1.81xQuick Ratio1.52x
    Trading Statistics
    Beta2.90Avg Volume413.85K
    52-Week High$46.5052-Week Low$0.75

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.05
    SMA 20$1.06
    SMA 50$1.16
    SMA 200$2.46
    EMA 10$0.99
    EMA 20$1.05
    EMA 50$1.31
    EMA 200$3.19

    MACD

    Line: -0.08Signal: -0.06Hist: -0.02

    ADX

    ADX: 16.7+DI: 19.5-DI: 31.5

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down100.0
    PSAR$1.29

    Bollinger Bands

    Upper Band$1.31
    Lower Band$0.81
    %B Position4672%(Upper)
    Band Width-0.19

    RSI (14-Day)

    Oversold
    29.0

    Momentum Oscillators

    Stoch %K3.4
    Stoch %D27.3
    Williams %R-99.3
    ROC (10d)-33.8%
    Momentum-0.36
    CCI (20d)-299.3
    MFI (14d)45.2

    Volatility Measures

    ATR (14d)$0.12(16.5%)
    StdDev (20d)0.12
    Hist Vol135.4%(High)

    Volume Flow

    VWAP$0.75
    OBV1.5B
    AD Line262.7B
    CMF (20d)-0.173

    Volume Metrics

    Avg Vol (20d)364.5K
    Vol Ratio0.7x
    VWMA (20d)$1.04

    Pivot Points

    R3$1.28
    R2$1.17
    R1$0.97
    Pivot Point$0.86
    S1$0.65
    S2$0.54
    S3$0.34

    Advanced Oscillators

    TSI-22.00
    Ultimate Osc27.6
    KST-74.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$166,131$145,954$263,922$145,380$162,910$50,277$149,325$641,141$2.66M$467,854$3.56M$2.46M
    Cost of Revenue$45,303$193,768$142,396$26,285$32,106$21,590$255,068$297,403$212,148$234,505$2.97M$255,772
    Gross Profit$120,828$-47,814$121,526$119,095$130,804$28,687$-105,743$343,738$2.44M$233,349$587,336$2.20M
    Operating Expenses$6.32M$9.16M$26.66M$7.13M$8.19M$8.58M$11.80M$10.58M$10.12M$10.49M$12.41M$11.14M
    R&D$4.15M$5.93M$5.10M$4.48M$4.69M$4.87M$4.81M$4.88M$5.61M$5.68M$6.18M$5.79M
    SG&A$1.50M$2.50M$1.87M$1.82M$2.60M$2.77M$5.82M$4.29M$3.13M$2.92M$4.40M$3.15M
    Operating Income$-6,200,783$-9,208,411$-26,541,784$-7,013,848$-8,057,764$-8,551,956$-11,907,024$-10,234,937$-7,679,962$-10,259,387$-11,825,194$-8,935,951
    Interest Income$-34,664$68,893$357,415$-42,765$-1,602$12,157$82,204$264,091$267,685$291,778$439,211$277,012
    Interest Expense$63,835$0$0$39,568$0$0$0$0$0$0$0$0
    Income Before Tax$-6,264,618$-9,139,518$-26,219,441$-7,053,416$-7,717,790$-7,521,267$-11,039,367$-9,674,266$-7,578,728$-9,289,279$-10,842,434$-8,095,775
    Income Tax Expense$19,168$520$-473,716$-1,166,593$12,327$12,004$-8,175$22,189$20,590$22,764$3.83M$-2,113,581
    Net Income$-6,283,786$-9,140,038$-25,745,725$-5,886,823$-7,730,117$-7,533,271$-11,031,192$-9,696,455$-7,599,318$-9,312,043$-14,676,455$-5,982,194
    EBITDA$-6,028,114$-8,952,966$-26,309,290$-6,743,268$-7,424,774$-7,252,979$-10,764,448$-9,587,122$-7,508,078$-9,250,484$-10,968,767$-8,076,447
    EBIT$-6,229,954$-9,208,411$-26,576,856$-7,010,651$-7,716,188$-7,533,424$-11,121,571$-9,938,357$-7,846,413$-9,581,057$-11,281,645$-8,372,787
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CODX

    News

    Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection

    Co-Diagnostics (CODX) is highlighting its PCR Pro® point-of-care platform's potential for plague diagnostics, following the death of a lab worker in Russia. While no plague-specific assay has been developed...

    TradingView•10/15/26•Somewhat-Bullish

    Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection

    Co-Diagnostics, Inc. (Nasdaq: CODX) is highlighting the capabilities of its Co-Dx PCR Pro® point-of-care platform for potential use in plague diagnostics...

    PR Newswire•10/15/26•Somewhat-Bullish

    Co-Diagnostics Secures Up to $3.1M Convertible Financing; Sets ATM Sweep, Collateral and Registration Terms

    Co-Diagnostics (CODX) has secured up to $3.1 million in senior secured convertible notes from J.J. Astor & Co., with an initial funding of $2.1 million. The financing package includes terms for weekly installments...

    TradingView•10/13/26•Somewhat-Bullish

    Ute Indian Tribe adopts Co-Diagnostics' PCR mos...

    The Ute Indian Tribe Mosquito Abatement Department has adopted Co-Diagnostics' Vector Smart® mosquito surveillance laboratory...

    Pluang•10/8/26•Neutral

    Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe

    Co-Diagnostics, Inc. has announced the first full Vector Smart® laboratory installation for a Native American tribe...

    PR Newswire•10/8/26•Bullish

    CODX Valuation and Fair Value

    P/E
    -0.0x
    Forward P/E
    15.4x
    P/FCF
    -0.1x
    PEG
    0.0x
    P/B
    0.2x
    See GNG's fair value

    CODX Profitability: Margins, ROIC and FCF

    Gross margin
    43.5%
    Operating margin
    -3732.0%
    Net margin
    0.0%
    ROE
    -174.8%
    FCF margin
    -3808.0%
    FCF yield
    -891.3%

    CODX Competitors

    CompanyTicker
    Neurosense Therapeutics LtdNRSN
    Enveric Biosciences IncENVB
    Nutriband Inc. WarrantNTRBW
    Traws Pharma IncTRAW
    FibroBiologics, Inc. Common StockFBLG
    Reviva Pharmaceuticals Holdings Inc.RVPH
    Skye Bioscience, Inc. Common StockSKYE
    Zhongchao IncZCMD

    Sector: Healthcare

    CODX Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    -404.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.25
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About CODX

    Does CODX pay dividends?

    Co-Diagnostics, Inc. Common Stock (CODX) does not currently pay a regular dividend.

    What is CODX's market cap?

    Co-Diagnostics, Inc. Common Stock (CODX) has a market capitalization of $6.49M with a current stock price of $0.72.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In